FICB for Femoral Neck Fractures

Phase-Based Progress Estimates
University of Virginia Medical Center, Charlottesville, VA
Femoral Neck Fractures+3 More
FICB - Procedure
All Sexes
What conditions do you have?

Study Summary

Regional anesthesia for hip fractures has been shown to decrease rates of delirium in elderly patients with hip fractures as well as improve pain compared to systemic opioids. The Pericapsular Nerve Group (PENG) block has recently received attention as an alternative approach to femoral nerve block and Fascia Iliaca Compartment Block (FICB). The investigators seek to evaluate if there is a difference between the PENG and FICB in terms of efficacy of pain control in ED patients presenting with hip fracture. We hypothesize that the PENG block may be superior based on previous research.

Eligible Conditions

  • Femoral Neck Fractures
  • Intertrochanteric Fractures

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 6 hours

6 hours
Opioid use
Pain score

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control

50 Total Participants · 2 Treatment Groups

Primary Treatment: FICB · No Placebo Group · N/A

ActiveComparator Group · 1 Intervention: FICB · Intervention Types: Procedure
ActiveComparator Group · 1 Intervention: PENG · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 hours

Trial Background

Prof. Matthew Kongkatong, MD
Principal Investigator
University of Virginia
Closest Location: University of Virginia Medical Center · Charlottesville, VA
2006First Recorded Clinical Trial
1 TrialsResearching Femoral Neck Fractures
58 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.